Immune perturbations in HIV-1–infected individuals who make broadly neutralizing antibodies

Science Immunology

Volumn 1, Issue 1, 2016, Pages

  Moody, M Anthony ^a   Pedroza Pacheco, Isabela ^b   Vandergrift, Nathan A ^a   Chui, Cecilia ^b   Lloyd, Krissey E ^a   Parks, Robert ^a   Soderberg, Kelly A ^a   Ogbe, Ane T ^b   Cohen, Myron S ^c   Liao, Hua Xin ^a   Gao, Feng ^a   McMichael, Andrew J ^b   Montefiori, David C ^a   Verkoczy, Laurent ^a   Kelsoe, Garnett ^a   Huang, Jinghe ^d   Shea, Patrick R ^e   Connors, Mark ^d   Borrow, Persephone ^b   Haynes, Barton F ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85010862425     PISSN: None     EISSN: 24709468     Source Type: Journal    
DOI: 10.1126/sciimmunol.aag0851     Document Type: Article

References (111)

1. A. S. Fauci, H. D. Marston, Ending AIDS—Is an HIV vaccine necessary? N. Engl. J. Med. 370, 495–498 (2014).
2. J. R. Mascola, B. F. Haynes, HIV-1 neutralizing antibodies: Understanding nature’s pathways. Immunol. Rev. 254, 225–244 (2013).
3. D. R. Burton, J. R. Mascola, Antibody responses to envelope glycoproteins in HIV-1 infection. Nat. Immunol. 16, 571–576 (2015).
4. S. Rerks-Ngarm, P. Pitisuttithum, S. Nitayaphan, J. Kaewkungwal, J. Chiu, R. Paris, N. Premsri, C. Namwat, M. de Souza, E. Adams, M. Benenson, S. Gurunathan, J. Tartaglia, J. G. McNeil, D. P. Francis, D. Stablein, D. L. Birx, S. Chunsuttiwat, C. Khamboonruang, P. Thongcharoen, M. L. Robb, N. L. Michael, P. Kunasol, J. H. Kim; MOPH–TAVEG Investigators, Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361, 2209–2220 (2009).
5. D. C. Montefiori, C. Karnasuta, Y. Huang, H. Ahmed, P. Gilbert, M. S. de Souza, R. McLinden, S. Tovanabutra, A. Laurence-Chenine, E. Sanders-Buell, M. A. Moody, M. Bonsignori, C. Ochsenbauer, J. Kappes, H. Tang, K. Greene, H. Gao, C. C. LaBranche, C. Andrews, V. R. Polonis, S. Rerks-Ngarm, P. Pitisuttithum, S. Nitayaphan, J. Kaewkungwal, S. G. Self, P. W. Berman, D. Francis, F. Sinangil, C. Lee, J. Tartaglia, M. L. Robb, B. F. Haynes, N. L. Michael, J. H. Kim, Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J. Infect. Dis. 206, 431–441 (2012).
6. S. M. Hammer, M. E. Sobieszczyk, H. Janes, S. T. Karuna, M. J. Mulligan, D. Grove, B. A. Koblin, S. P. Buchbinder, M. C. Keefer, G. D. Tomaras, N. Frahm, J. Hural, C. Anude, B. S. Graham, M. E. Enama, E. Adams, E. DeJesus, R. M. Novak, I. Frank, C. Bentley, S. Ramirez, R. Fu, R. A. Koup, J. R. Mascola, G. J. Nabel, D. C. Montefiori, J. Kublin, M. J. McElrath, L. Corey, P. B. Gilbert; HVTN 505 Study Team, Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N. Engl. J. Med. 369, 2083–2092 (2013).
7. P. Hraber, M. S. Seaman, R. T. Bailer, J. R. Mascola, D. C. Montefiori, B. T. Korber, Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection. AIDS 28, 163–169 (2014).
8. N. A. Doria-Rose, R. M. Klein, M. G. Daniels, S. O’Dell, M. Nason, A. Lapedes, T. Bhattacharya, S. A. Migueles, R. T. Wyatt, B. T. Korber, J. R. Mascola, M. Connors, Breadth of human immunodeficiency virus-specific neutralizing activity in sera: Clustering analysis and association with clinical variables. J. Virol. 84, 1631–1636 (2010).
9. D. N. Sather, J. Armann, L. K. Ching, A. Mavrantoni, G. Sellhorn, Z. Caldwell, X. Yu, B. Wood, S. Self, S. Kalams, L. Stamatatos, Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J. Virol. 83, 757–769 (2009).
10. L. M. Walker, M. D. Simek, F. Priddy, J. S. Gach, D. Wagner, M. B. Zwick, S. K. Phogat, P. Poignard, D. R. Burton, A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLOS Pathog. 6, e1001028 (2010).
11. + T cell decline and high viral load during acute infection. J. Virol. 85, 4828–4840 (2011).
12. B. F. Haynes, L. Verkoczy, AIDS/HIV. Host controls of HIV neutralizing antibodies. Science 344, 588–589 (2014).
13. B. F. Haynes, J. Fleming, E. W. St. Clair, H. Katinger, G. Stiegler, R. Kunert, J. Robinson, R. M. Scearce, K. Plonk, H. F. Staats, T. L. Ortel, H.-X. Liao, S. M. Alam, Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 308, 1906–1908 (2005).
14. H. Mouquet, J. F. Scheid, M. J. Zoller, M. Krogsgaard, R. G. Ott, S. Shukair, M. N. Artyomov, J. Pietzsch, M. Connors, F. Pereyra, B. D. Walker, D. D. Ho, P. C. Wilson, M. S. Seaman, H. N. Eisen, A. K. Chakraborty, T. J. Hope, J. V. Ravetch, H. Wardemann, M. C. Nussenzweig, Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature 467, 591–595 (2010).
15. B. F. Haynes, M. A. Moody, L. Verkoczy, G. Kelsoe, S. M. Alam, Antibody polyspecificity and neutralization of HIV-1: A hypothesis. Hum. Antibodies 14, 59–67 (2005).
16. B. F. Haynes, G. Kelsoe, S. C. Harrison, T. B. Kepler, B-cell–lineage immunogen design in vaccine development with HIV-1 as a case study. Nat. Biotechnol. 30, 423–433 (2012).
17. F. D. Batista, M. S. Neuberger, Affinity dependence of the B cell response to antigen: A threshold, a ceiling, and the importance of off-rate. Immunity 8, 751–759 (1998).
18. J. Zhang, E. I. Shakhnovich, Optimality of mutation and selection in germinal centers. PLOS Comput. Biol. 6, e1000800 (2010).
19. T. B. Kepler, A. S. Perelson, Somatic hypermutation in B cells: An optimal control treatment. J. Theor. Biol. 164, 37–64 (1993).
20. C. Chen, Z. Nagy, M. Z. Radic, R. R. Hardy, D. Huszar, S. A. Camper, M. Weigert, The site and stage of anti-DNA B-cell deletion. Nature 373, 252–255 (1995).
21. L. Verkoczy, M. Diaz, T. M. Holl, Y.-B. Ouyang, H. Bouton-Verville, S. M. Alam, H.-X. Liao, G. Kelsoe, B. F. Haynes, Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance. Proc. Natl. Acad. Sci. U.S.A. 107, 181–186 (2010).
22. L knockin mice reveals multiple tolerance controls. J. Immunol. 187, 3785–3797 (2011).
23. L. Verkoczy, Y. Chen, J. Zhang, H. Bouton-Verville, A. Newman, B. Lockwood, R. M. Scearce, D. C. Montefiori, S. M. Dennison, S.-M. Xia, K.-K. Hwang, H.-X. Liao, S. M. Alam, B. F. Haynes, Induction of HIV-1 broad neutralizing antibodies in 2F5 knock-in mice: Selection against membrane proximal external region–associated autoreactivity limits T-dependent responses. J. Immunol. 191, 2538–2550 (2013).
24. Y. Chen, J. Zhang, K.-K. Hwang, H. Bouton-Verville, S.-M. Xia, A. Newman, Y.-B. Ouyang, B. F. Haynes, L. Verkoczy, Common tolerance mechanisms, but distinct cross-reactivities associated with gp41 and lipids, limit production of HIV-1 broad neutralizing antibodies 2F5 and 4E10. J. Immunol. 191, 1260–1275 (2013).
25. S. Shiokawa, F. Mortari, J. O. Lima, C. Nuñez, F. E. Bertrand III, P. M. Kirkham, S. Zhu, A. P. Dasanayake, H. W. Schroeder Jr., IgM heavy chain complementarity-determining region 3 diversity is constrained by genetic and somatic mechanisms until two months after birth. J. Immunol. 162, 6060–6070 (1999).
26. E. Meffre, M. Milili, C. Blanco-Betancourt, H. Antunes, M. C. Nussenzweig, C. Schiff, Immunoglobulin heavy chain expression shapes the B cell receptor repertoire in human B cell development. J. Clin. Invest. 108, 879–886 (2001).
27. R. T. Canoso, L. I. Zon, J. E. Groopman, Anticardiolipin antibodies associated with HTLV-III infection. Br. J. Haematol. 65, 495–498 (1987).
28. R. G. Kopelman, S. Zolla-Pazner, Association of human immunodeficiency virus infection and autoimmune phenomena. Am. J. Med. 84, 82–88 (1988).
29. W. J. W. Morrow, D. A. Isenberg, R. E. Sobol, R. B. Stricker, T. Kieber-Emmons, AIDS virus infection and autoimmunity: A perspective of the clinical, immunological, and molecular origins of the autoallergic pathologies associated with HIV disease. Clin. Immunol. Immunopathol. 58, 163–180 (1991).
30. G. Zandman-Goddard, Y. Shoenfeld, HIV and autoimmunity. Autoimmun. Rev. 1, 329–337 (2002).
31. J. D. Reveille, The changing spectrum of rheumatic disease in human immunodeficiency virus infection. Semin. Arthritis Rheum. 30, 147–166 (2000).
32. D. Sène, J.-C. Piette, P. Cacoub, Antiphospholipid antibodies, antiphospholipid syndrome and infections. Autoimmun. Rev. 7, 272–277 (2008).
33. L. Iordache, O. Launay, O. Bouchaud, V. Jeantils, C. Goujard, F. Boue, P. Cacoub, T. Hanslik, A. Mahr, O. Lambotte, O. Fain, Autoimmune diseases in HIV-infected patients: 52 cases and literature review. Autoimmun. Rev. 13, 850–857 (2014).
34. + memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses. Immunity 39, 758–769 (2013).
35. reg cells in humoral immunity. Int. Immunol. 26, 61–69 (2014).
36. H. W. Lim, P. Hillsamer, C. H. Kim, Regulatory T cells can migrate to follicles upon T cell activation and suppress GC-Th cells and GC-Th cell-driven B cell responses. J. Clin. Invest. 114, 1640–1649 (2004).
37. Y. Chung, S. Tanaka, F. Chu, R. I. Nurieva, G. J. Martinez, S. Rawal, Y.-H. Wang, H. Lim, J. M. Reynolds, X.-H. Zhou, H.-M. Fan, Z.-M. Liu, S. S. Neelapu, C. Dong, Follicular regulatory T cells expressing Foxp3 and Bcl-6 suppress germinal center reactions. Nat. Med. 17, 983–988 (2011).
38. + follicular regulatory T cells control the germinal center response. Nat. Med. 17, 975–982 (2011).
39. + follicular regulatory T cells. J. Immunol. 187, 4553–4560 (2011).
40. P. T. Sage, A. M. Paterson, S. B. Lovitch, A. H. Sharpe, The coinhibitory receptor CTLA-4 controls B cell responses by modulating T follicular helper, T follicular regulatory, and T regulatory cells. Immunity 41, 1026–1039 (2014).
41. P. T. Sage, L. M. Francisco, C. V. Carman, A. H. Sharpe, The receptor PD-1 controls follicular regulatory T cells in the lymph nodes and blood. Nat. Immunol. 14, 152–161 (2013).
42. J. B. Wing, W. Ise, T. Kurosaki, S. Sakaguchi, Regulatory T cells control antigen-specific expansion of Tfh cell number and humoral immune responses via the coreceptor CTLA-4. Immunity 41, 1013–1025 (2014).
43. H. C. Lane, H. Masur, L. C. Edgar, G. Whalen, A. H. Rook, A. S. Fauci, Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N. Engl. J. Med. 309, 453–458 (1983).
44. + natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol. Rev. 212, 8–27 (2006).
45. N. Ohkura, Y. Kitagawa, S. Sakaguchi, Development and maintenance of regulatory T cells. Immunity 38, 414–423 (2013).
46. + T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion. Immunity 34, 108–121 (2011).
47. C. S. Ma, E. K. Deenick, M. Batten, S. G. Tangye, The origins, function, and regulation of T follicular helper cells. J. Exp. Med. 209, 1241–1253 (2012).
48. N. Simpson, P. A. Gatenby, A. Wilson, S. Malik, D. A. Fulcher, S. G. Tangye, H. Manku, T. J. Vyse, G. Roncador, G. A. Huttley, C. C. Goodnow, C. G. Vinuesa, M. C. Cook, Expansion of circulating T cells resembling follicular helper T cells is a fixed phenotype that identifies a subset of severe systemic lupus erythematosus. Arthritis Rheum. 62, 234–244 (2010).
49. V. Velu, R. D. Shetty, M. Larsson, E. M. Shankar, Role of PD-1 co-inhibitory pathway in HIV infection and potential therapeutic options. Retrovirology 12, 14 (2015).
50. E. Gianchecchi, D. V. Delfino, A. Fierabracci, Recent insights into the role of the PD-1/PD-L1 pathway in immunological tolerance and autoimmunity. Autoimmun. Rev. 12, 1091–1100 (2013).
51. J.-H. Chang, Y. Chung, Regulatory T cells in B cell follicles. Immune Netw. 14, 227–236 (2014).
52. P. T. Sage, A. H. Sharpe, T follicular regulatory cells in the regulation of B cell responses. Trends Immunol. 36, 410–418 (2015).
53. P. T. Sage, D. Alvarez, J. Godec, U. H. von Andrian, A. H. Sharpe, Circulating T follicular regulatory and helper cells have memory-like properties. J. Clin. Invest. 124, 5191–5204 (2014).
54. M. Espeli, M. Linterman, Eds., T Follicular Helper Cells. Methods and Protocols, vol. 1291 of Methods in Molecular Biology (Springer, 2015).
55. + follicular regulatory T (TFR) cells in CHB or CHC patients. J. Transl. Med. 12, 251 (2014).
56. + T cell dysfunction during chronic infection. Immunity 40, 289–302 (2014).
57. + T cell suppressor function. Eur. J. Immunol. 34, 366–376 (2004).
58. C.-T. Huang, C. J. Workman, D. Flies, X. Pan, A. L. Marson, G. Zhou, E. L. Hipkiss, S. Ravi, J. Kowalski, H. I. Levitsky, J. D. Powell, D. M. Pardoll, C. G. Drake, D. A. A. Vignali, Role of LAG-3 in regulatory T cells. Immunity 21, 503–513 (2004).
59. International MHC and Autoimmunity Genetics Network, J. D. Rioux, P. Goyette, T. J. Vyse, L. Hammarström, M. M. A. Fernando, T. Green, P. L. De Jager, S. Foisy, J. Wang, P. I. W. de Bakker, S. Leslie, G. McVean, L. Padyukov, L. Alfredsson, V. Annese, D. A. Hafler, Q. Pan-Hammarström, R. Matell, S. J. Sawcer, A. D. Compston, B. A. C. Cree, D. B. Mirel, M. J. Daly, T. W. Behrens, L. Klareskog, P. K. Gregersen, J. R. Oksenberg, S. L. Hauser, Mapping of multiple susceptibility variants within the MHC region for 7 immune-mediated diseases. Proc. Natl. Acad. Sci. U.S.A. 106, 18680–18685 (2009).
60. J. D. Lifson, M. Piatak Jr., J. L. Rossio, J. Bess Jr., E. Chertova, D. Schneider, R. Kiser, V. Coalter, B. Poore, R. Imming, R. C. Desrosiers, L. E. Henderson, L. O. Arthur, Whole inactivated SIV virion vaccines with functional envelope glycoproteins: Safety, immunogenicity, and activity against intrarectal challenge. J. Med. Primatol. 31, 205–216 (2002).
61. J. D. Lifson, J. L. Rossio, M. Piatak Jr., J. Bess Jr., E. Chertova, D. K. Schneider, V. J. Coalter, B. Poore, R. F. Kiser, R. J. Imming, A. J. Scarzello, L. E. Henderson, W. G. Alvord, V. M. Hirsch, R. E. Benveniste, L. O. Arthur, Evaluation of the safety, immunogenicity, and protective efficacy of whole inactivated simian immunodeficiency virus (SIV) vaccines with conformationally and functionally intact envelope glycoproteins. AIDS Res. Hum. Retroviruses 20, 772–787 (2004).
62. T. Tong, E. T. Crooks, K. Osawa, J. E. Robinson, M. Barnes, C. Apetrei, J. M. Binley, Multi-parameter exploration of HIV-1 virus-like particles as neutralizing antibody immunogens in guinea pigs, rabbits and macaques. Virology 456–457, 55–69 (2014).
63. R. L. Willey, R. Byrum, M. Piatak, Y. B. Kim, M. W. Cho, J. L. Rossio Jr., J. Bess Jr., T. Igarashi, Y. Endo, L. O. Arthur, J. D. Lifson, M. A. Martin, Control of viremia and prevention of simian-human immunodeficiency virus-induced disease in rhesus macaques immunized with recombinant vaccinia viruses plus inactivated simian immunodeficiency virus and human immunodeficiency virus type 1 particles. J. Virol. 77, 1163–1174 (2003).
64. J. M. Kovacs, J. P. Nkolola, H. Peng, A. Cheung, J. Perry, C. A. Miller, M. S. Seaman, D. H. Barouch, B. Chen, HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120. Proc. Natl. Acad. Sci. U.S.A. 109, 12111–12116 (2012).
65. C. A. Bricault, J. M. Kovacs, J. P. Nkolola, K. Yusim, E. E. Giorgi, J. L. Shields, J. Perry, C. L. Lavine, A. Cheung, K. Ellingson-Strouss, C. Rademeyer, G. E. Gray, C. Williamson, L. Stamatatos, M. S. Seaman, B. T. Korber, B. Chen, D. H. Barouch, A multivalent clade C HIV-1 Env trimer cocktail elicits a higher magnitude of neutralizing antibodies than any individual component. J. Virol. 89, 2507–2519 (2015).
66. R. W. Sanders, M. J. van Gils, R. Derking, D. Sok, T. J. Ketas, J. A. Burger, G. Ozorowski, A. Cupo, C. Simonich, L. Goo, H. Arendt, H. J. Kim, J. H. Lee, P. Pugach, M. Williams, G. Debnath, B. Moldt, M. J. van Breemen, G. Isik, M. Medina-Ramírez, J. W. Back, W. C. Koff, J.-P. Julien, E. G. Rakasz, M. S. Seaman, M. Guttman, K. K. Lee, P. J. Klasse, C. LaBranche, W. R. Schief, I. A. Wilson, J. Overbaugh, D. R. Burton, A. B. Ward, D. C. Montefiori, H. Dean, J. P. Moore, HIV-1 neutralizing antibodies induced by native-like envelope trimers. Science 349, aac4223 (2015).
67. E. S. Gray, N. Taylor, D. Wycuff, P. L. Moore, G. D. Tomaras, C. K. Wibmer, A. Puren, A. DeCamp, P. B. Gilbert, B. Wood, D. C. Montefiori, J. M. Binley, G. M. Shaw, B. F. Haynes, J. R. Mascola, L. Morris, Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors. J. Virol. 83, 8925–8937 (2009).
68. INSIGHT START Study Group, J. D. Lundgren, A. G. Babiker, F. Gordin, S. Emery, B. Grund, S. Sharma, A. Avihingsanon, D. A. Cooper, G. Fätkenheuer, J. M. Llibre, J. M. Molina, P. Munderi, M. Schechter, R. Wood, K. L. Klingman, S. Collins, H. C. Lane, A. N. Phillips, J. D. Neaton, Initiation of antiretroviral therapy in early asymptomatic HIV infection. N. Engl. J. Med. 373, 795–807 (2015).
69. T. H. Finkel, G. Tudor-Williams, N. K. Banda, M. F. Cotton, T. Curiel, C. Monks, T. W. Baba, R. M. Ruprecht, A. Kupfer, Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes. Nat. Med. 1, 129–134 (1995).
70. M. F. Chevalier, L. Weiss, The split personality of regulatory T cells in HIV infection. Blood 121, 29–37 (2013).
71. P. L. Moore, C. Williamson, L. Morris, Virological features associated with the development of broadly neutralizing antibodies to HIV-1. Trends Microbiol. 23, 204–211 (2015).
72. S. Crotty, T follicular helper cell differentiation, function, and roles in disease. Immunity 41, 529–542 (2014).
73. J. A. Harker, G. M. Lewis, L. Mack, E. I. Zuniga, Late interleukin-6 escalates T follicular helper cell responses and controls a chronic viral infection. Science 334, 825–829 (2011).
74. L. M. Fahey, E. B. Wilson, H. Elsaesser, C. D. Fistonich, D. B. McGavern, D. G. Brooks, Viral persistence redirects CD4 T cell differentiation toward T follicular helper cells. J. Exp. Med. 208, 987–999 (2011).
75. M. Lindqvist, J. van Lunzen, D. Z. Soghoian, B. D. Kuhl, S. Ranasinghe, G. Kranias, M. D. Flanders, S. Cutler, N. Yudanin, M. I. Muller, I. Davis, D. Farber, P. Hartjen, F. Haag, G. Alter, J. Schulze zur Wiesch, H. Streeck, Expansion of HIV-specific T follicular helper cells in chronic HIV infection. J. Clin. Invest. 122, 3271–3280 (2012).
76. M. Perreau, A.-L. Savoye, E. De Crignis, J.-M. Corpataux, R. Cubas, E. K. Haddad, L. De Leval, C. Graziosi, G. Pantaleo, Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production. J. Exp. Med. 210, 143–156 (2013).
77. R. A. Cubas, J. C. Mudd, A.-L. Savoye, M. Perreau, J. van Grevenynghe, T. Metcalf, E. Connick, A. Meditz, G. J. Freeman, G. Abesada-Terk Jr., J. M. Jacobson, A. D. Brooks, S. Crotty, J. D. Estes, G. Pantaleo, M. M. Lederman, E. K. Haddad, Inadequate T follicular cell help impairs B cell immunity during HIV infection. Nat. Med. 19, 494–499 (2013).
78. + helper T cells and B cell activation predict the breadth of neutralizing antibody responses in chronic HIV-1 infection. J. Virol. 88, 13310–13321 (2014).
79. FH in chronic infection. J. Immunol. 195, 3237–3247 (2015).
80. B. Miles, S. M. Miller, J. M. Folkvord, A. Kimball, M. Chamanian, A. L. Meditz, T. Arends, M. D. McCarter, D. N. Levy, E. G. Rakasz, P. J. Skinner, E. Connick, Follicular regulatory T cells impair follicular T helper cells in HIV and SIV infection. Nat. Commun. 6, 8608 (2015).
81. L. Colineau, A. Rouers, T. Yamamoto, Y. Xu, A. Urrutia, H.-P. Pham, S. Cardinaud, A. Samri, K. Dorgham, P.-G. Coulon, R. Cheynier, A. Hosmalin, E. Oksenhendler, A. Six, A. D. Kelleher, J. Zaunders, R. A. Koup, B. Autran, A. Moris, S. Graff-Dubois, HIV-infected spleens present altered follicular helper T cell (Tfh) subsets and skewed B cell maturation. PLOS One 10, e0140978 (2015).
82. M. Aloulou, E. J. Carr, M. Gador, A. Bignon, R. S. Liblau, N. Fazilleau, M. A. Linterman, Follicular regulatory T cells can be specific for the immunizing antigen and derive from naive T cells. Nat. Commun. 7, 10579 (2016).
83. G. Yang, T. M. Holl, Y. Liu, Y. Li, X. Lu, N. I. Nicely, T. B. Kepler, S. M. Alam, H.-X. Liao, D. W. Cain, L. Spicer, J. L. VandeBerg, B. F. Haynes, G. Kelsoe, Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies. J. Exp. Med. 210, 241–256 (2013).
84. a-restricted B cell receptor interactions with the HIV-1 envelope gp41 membrane proximal external region. PLOS One 4, e7215 (2009).
85. C. Doyle-Cooper, K. E. Hudson, A. B. Cooper, T. Ota, P. Skog, P. E. Dawson, M. B. Zwick, W. R. Schief, D. R. Burton, D. Nemazee, Immune tolerance negatively regulates B cells in knock-in mice expressing broadly neutralizing HIV antibody 4E10. J. Immunol. 191, 3186–3191 (2013).
86. M. Bonsignori, K. Wiehe, S. K. Grimm, R. Lynch, G. Yang, D. M. Kozink, F. Perrin, A. J. Cooper, K.-K. Hwang, X. Chen, M. Liu, K. McKee, R. J. Parks, J. Eudailey, M. Wang, M. Clowse, L. G. Criscione-Schreiber, M. A. Moody, M. E. Ackerman, S. D. Boyd, F. Gao, G. Kelsoe, L. Verkoczy, G. D. Tomaras, H.-X. Liao, T. B. Kepler, D. C. Montefiori, J. R. Mascola, B. F. Haynes, An autoreactive antibody from an SLE/HIV-1 individual broadly neutralizes HIV-1. J. Clin. Invest. 124, 1835–1843 (2014).
87. P. Sharma, J. P. Allison, The future of immune checkpoint therapy. Science 348, 56–61 (2015).
88. S. Chakarov, N. Fazilleau, Monocyte-derived dendritic cells promote T follicular helper cell differentiation. EMBO Mol. Med. 6, 590–603 (2014).
89. D. C. Rookhuizen, A. L. DeFranco, Toll-like receptor 9 signaling acts on multiple elements of the germinal center to enhance antibody responses. Proc. Natl. Acad. Sci. U.S.A. 111, E3224–E3233 (2014).
90. H.-X. Liao, R. Lynch, T. Zhou, F. Gao, S. M. Alam, S. D. Boyd, A. Z. Fire, K. M. Roskin, C. A. Schramm, Z. Zhang, J. Zhu, L. Shapiro; NISC Comparative Sequencing Program, J. C. Mullikin, S. Gnanakaran, P. Hraber, K. Wiehe, G. Kelsoe, G. Yang, S.-M. Xia, D. C. Montefiori, R. Parks, K. E. Lloyd, R. M. Scearce, K. A. Soderberg, M. Cohen, G. Kamanga, M. K. Louder, L. M. Tran, Y. Chen, F. Cai, S. Chen, S. Moquin, X. Du, M. G. Joyce, S. Srivatsan, B. Zhang, A. Zheng, G. M. Shaw, B. H. Hahn, T. B. Kepler, B. T. M. Korber, P. D. Kwong, J. R. Mascola, B. F. Haynes, Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 496, 469–476 (2013).
91. B. S. Briney, J. R. Willis, J. E. Crowe Jr., Human peripheral blood antibodies with long HCDR3s are established primarily at original recombination using a limited subset of germline genes. PLOS One 7, e36750 (2012).
92. Z. Sabouri, P. Schofield, K. Horikawa, E. Spierings, D. Kipling, K. L. Randall, D. Langley, B. Roome, R. Vazquez-Lombardi, R. Rouet, J. Hermes, T. D. Chan, R. Brink, D. K. Dunn-Walters, D. Christ, C. C. Goodnow, Redemption of autoantibodies on anergic B cells by variable-region glycosylation and mutation away from self-reactivity. Proc. Natl. Acad. Sci. U.S.A. 111, E2567–E2575 (2014).
93. R. Zhang, L. Verkoczy, K. Wiehe, S. M. Alam, N. I. Nicely, S. Santra, T. Bradley, C. W. Pemble IV, J. Zhang, F. Gao, D. C. Montefiori, H. Bouton-Verville, G. Kelsoe, K. Larimore, P. D. Greenberg, R. Parks, A. Foulger, J. N. Peel, K. Luo, X. Lu, A. M. Trama, N. Vandergrift, G. D. Tomaras, T. B. Kepler, M. A. Moody, H.-X. Liao, B. F. Haynes, Initiation of immune tolerance–controlled HIV gp41 neutralizing B cell lineages. Sci. Transl. Med. 8, 336ra62 (2016).
94. L. M. Walker, S. K. Phogat, P.-Y. Chan-Hui, D. Wagner, P. Phung, J. L. Goss, T. Wrin, M. D. Simek, S. Fling, J. L. Mitcham, J. K. Lehrman, F. H. Priddy, O. A. Olsen, S. M. Frey, P. W. Hammond; Protocol G Principal Investigators, S. Kaminsky, T. Zamb, M. Moyle, W. C. Koff, P. Poignard, D. R. Burton, Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326, 285–289 (2009).
95. M. Bonsignori, K.-K. Hwang, X. Chen, C.-Y. Tsao, L. Morris, E. Gray, D. J. Marshall, J. A. Crump, S. H. Kapiga, N. E. Sam, F. Sinangil, M. Pancera, Y. Yongping, B. Zhang, J. Zhu, P. D. Kwong, S. O’Dell, J. R. Mascola, L. Wu, G. J. Nabel, S. Phogat, M. S. Seaman, J. F. Whitesides, M. A. Moody, G. Kelsoe, X. Yang, J. Sodroski, G. M. Shaw, D. C. Montefiori, T. B. Kepler, G. D. Tomaras, S. M. Alam, H.-X. Liao, B. F. Haynes, Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J. Virol. 85, 9998–10009 (2011).
96. A. T. McGuire, A. M. Dreyer, S. Carbonetti, A. Lippy, J. Glenn, J. F. Scheid, H. Mouquet, L. Stamatatos, Antigen modification regulates competition of broad and narrow neutralizing HIV antibodies. Science 346, 1380–1383 (2014).
97. H. Wardemann, S. Yurasov, A. Schaefer, J. W. Young, E. Meffre, M. C. Nussenzweig, Predominant autoantibody production by early human B cell precursors. Science 301, 1374–1377 (2003).
98. + memory B cells. Immunity 26, 205–213 (2007).
99. G. D. Tomaras, J. M. Binley, E. S. Gray, E. T. Crooks, K. Osawa, P. L. Moore, N. Tumba, T. Tong, X. Shen, N. L. Yates, J. Decker, C. K. Wibmer, F. Gao, S. M. Alam, P. Easterbrook, S. Abdool Karim, G. Kamanga, J. A. Crump, M. Cohen, G. M. Shaw, J. R. Mascola, B. F. Haynes, D. C. Montefiori, L. Morris, Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals. J. Virol. 85, 11502–11519 (2011).
100. P. R. Rosenbaum, D. B. Rubin, The central role of the propensity score in observational studies for causal effects. Biometrika 70, 41–55 (1983).
101. J. J. Heckman, Sample selection bias as a specification error. Econometrica 47, 153–161 (1979).
102. K. Pearson, On lines and planes of closest fit to systems of points in space. Philos. Mag. 2, 559–572 (1901).
103. H. Hotelling, Analysis of a complex of statistical variables into principal components. J. Educ. Psychol. 24, 417–441 (1933).
104. J. E. Jackson, A User’s Guide to Principal Components (John Wiley & Sons, 1991).
105. M. S. Seaman, H. Janes, N. Hawkins, L. E. Grandpre, C. Devoy, A. Giri, R. T. Coffey, L. Harris, B. Wood, M. G. Daniels, T. Bhattacharya, A. Lapedes, V. R. Polonis, F. E. McCutchan, P. B. Gilbert, S. G. Self, B. T. Korber, D. C. Montefiori, J. R. Mascola, Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J. Virol. 84, 1439–1452 (2010).
106. R. M. Lynch, L. Tran, M. K. Louder, S. D. Schmidt, M. Cohen; CHAVI 001 Clinical Team Members, R. DerSimonian, Z. Euler, E. S. Gray, S. Abdool Karim, J. Kirchherr, D. C. Montefiori, S. Sibeko, K. Soderberg, G. Tomaras, Z.-Y. Yang, G. J. Nabel, H. Schuitemaker, L. Morris, B. F. Haynes, J. R. Mascola, The development of CD4 binding site antibodies during HIV-1 infection. J. Virol. 86, 7588–7595 (2012).
107. H.-X. Liao, X. Chen, S. Munshaw, R. Zhang, D. J. Marshall, N. Vandergrift, J. F. Whitesides, X. Lu, J.-S. Yu, K.-K. Hwang, F. Gao, M. Markowitz, S. L. Heath, K. J. Bar, P. A. Goepfert, D. C. Montefiori, G. C. Shaw, S. M. Alam, D. M. Margolis, T. N. Denny, S. D. Boyd, E. Marshal, M. Egholm, B. B. Simen, B. Hanczaruk, A. Z. Fire, G. Voss, G. Kelsoe, G. D. Tomaras, M. A. Moody, T. B. Kepler, B. F. Haynes, Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated. J. Exp. Med. 208, 2237–2249 (2011).
108. M. A. Moody, R. Zhang, E. B. Walter, C. W. Woods, G. S. Ginsburg, M. T. McClain, T. N. Denny, X. Chen, S. Munshaw, D. J. Marshall, J. F. Whitesides, M. S. Drinker, J. D. Amos, T. C. Gurley, J. A. Eudailey, A. Foulger, K. R. DeRosa, R. Parks, R. R. Meyerhoff, J.-S. Yu, D. M. Kozink, B. E. Barefoot, E. A. Ramsburg, S. Khurana, H. Golding, N. A. Vandergrift, S. M. Alam, G. D. Tomaras, T. B. Kepler, G. Kelsoe, H.-X. Liao, B. F. Haynes, H3N2 influenza infection elicits more cross-reactive and less clonally expanded anti-hemagglutinin antibodies than influenza vaccination. PLOS One 6, e25797 (2011).
109. -T cells by T-cell receptor stimulation is transforming growth factor-b-dependent but does not confer a regulatory phenotype. Blood 110, 2983–2990 (2007).
110. + T regulatory cell subset in humans. J. Immunol. 190, 2001–2008 (2013).
111. Y. Benjamini, Y. Hochberg, Controlling the false discovery rate: A practical and powerful approach to multiple testing. J. R. Stat. Soc. B 57, 289–300 (1995).